<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34067647</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1220</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10051220</ELocationID><Abstract><AbstractText>(1) Background: The aim of this longitudinal study was to evaluate the association between disease progression according to the Milano-Torino staging (MITOS) system and long-term survival in Chinese patients with amyotrophic lateral sclerosis (ALS). We also examined factors affecting MITOS progression. (2) Methods: Patients were enrolled and underwent follow-up at 6, 12, 18, and 24 months, and their demographic and clinical data, including the Milano-Torino stage, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score and neuropsychiatric data, were evaluated. The sensitivity and specificity of predicting survival outcomes based on MITOS progression and ALSFRS-R score decline from baseline to 6 months were compared. The associations between MITOS progression from baseline to 6 months and survival outcome at 12, 18 and 24 months were examined, and factors associated with disease progression were evaluated with subgroup analyses. (3) Results: Among the 100 patients included, 74% were in stage 0 at baseline, and approximately 95% progressed to a higher stage of the MITOS system at 24 months. MITOS progression from baseline to 6 months and ALSFRS-R decline showed comparable value for predicting survival at 12, 18, and 24 months. MITOS progression from baseline to 6 months is strongly associated with death outcomes. Older age at onset and increased depression and anxiety scores may be related to disease progression. (4) Conclusions: MITOS progression during the early disease course could serve as a prognostic marker of long-term survival and may have utility in clinical trials. Age at onset and diagnosis and neuropsychiatric factors might be associated with disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ruojie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3841-2620</Identifier><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Minying</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82001332</GrantID><Agency>the Young Scientist Fund of National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2017YFC0907703</GrantID><Agency>the National Key Research and Development Program of China</Agency><Country/></Grant><Grant><GrantID>N/A</GrantID><Agency>Guangdong Provincial Engineering Center For Major Neurological Disease Treatment</Agency><Country/></Grant><Grant><GrantID>N/A</GrantID><Agency>Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease</Agency><Country/></Grant><Grant><GrantID>N/A</GrantID><Agency>Guangdong Provincial Clinical Research Center for Neurological Diseases</Agency><Country/></Grant><Grant><GrantID>2015B050501003</GrantID><Agency>the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003679" MajorTopicYN="N">Deglutition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="Y">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006305" MajorTopicYN="Y">Health Status Indicators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012119" MajorTopicYN="N">Respiration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="N">Self Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Milano&#x2013;Torino staging</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">long-term survival</Keyword><Keyword MajorTopicYN="N">neuropsychiatric factors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34067647</ArticleId><ArticleId IdType="pmc">PMC8156970</ArticleId><ArticleId IdType="doi">10.3390/cells10051220</ArticleId><ArticleId IdType="pii">cells10051220</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishiet A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Biguzzi S., Guidi C., Sette E., Terlizzi E., Ravasio A., Casmiro M., Salvi F., Liguori R., Rizzi R., et al. Heterogeneity in ALSFRS-R decline and survival: A population-based study in Italy. Neurol. Sci. 2015;36:2243&#x2013;2252. doi: 10.1007/s10072-015-2343-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-015-2343-6</ArticleId><ArticleId IdType="pubmed">26205535</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M., Jones A., Talbot K., Al-Chalabi A., Turner M.R. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph. Later Scler. Frontotemporal Degener. 2016;17:414&#x2013;425. doi: 10.3109/21678421.2016.1140786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId><ArticleId IdType="pmc">PMC4950444</ArticleId><ArticleId IdType="pubmed">26864085</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V., Drory V.E., Leigh P.N., Ludolph A., Robberecht W., Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 2009;10:378&#x2013;383. doi: 10.3109/17482960902803432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902803432</ArticleId><ArticleId IdType="pubmed">19922128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009;66:235&#x2013;244. doi: 10.1002/ana.21743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21743</ArticleId><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Hammond E.R., Mora G., Bonito V., Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2015;86:38&#x2013;44. doi: 10.1136/jnnp-2013-306589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche J.C., Rojas-Garcia R., Scott K.M., Scotton W., Ellis C.E., Burman R., Wijesekera L., Turner M.R., Leigh P.N., Shaw C.E., et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847&#x2013;852. doi: 10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramacere I., Bella E.D., Chi&#xf2; A., Mora G., Filippini G., Lauria G. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2015;86:1180&#x2013;1185. doi: 10.1136/jnnp-2014-310176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-310176</ArticleId><ArticleId IdType="pubmed">25886781</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Jones A., Jivraj N., Steen N.I., Young C.A., Shaw P.J., Turner M.R., Leigh P.N., Al-Chalabi A. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J. Neurol. Neurosurg. Psychiatry. 2015;86:45&#x2013;49. doi: 10.1136/jnnp-2013-306865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306865</ArticleId><ArticleId IdType="pubmed">24463480</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Beltran S., Lautrette G., Bakkouche S., Couratier P. Staging amyotrophic lateral sclerosis: A new focus on progression. Rev. Neurol. 2019;175:277&#x2013;282. doi: 10.1016/j.neurol.2018.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2018.09.017</ArticleId><ArticleId IdType="pubmed">30606512</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Al Khleifat A., Stahl D.R., La Torre C.L., Murphy C., Young C., Shaw P.J., Leigh P.N., Al-Chalabi A. Comparison of the King&#x2019;s and MiToS staging systems for ALS. Amyotroph. Lateral Scler. Front. Degener. 2017;18:227&#x2013;232. doi: 10.1080/21678421.2016.1265565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1265565</ArticleId><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H.-J., Debray T.P.A., Visser A.E., van Eijk R.P.A., Rooney J.P.K., Calvo A., Martin S., McDermott C.J., Thompson A.G., Pinto S., et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T., Gaur N., Stubendorff B., Rodiger A., Witte O.W., Grosskreutz J. Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis. J. Neurol. Sci. 2019;397:92&#x2013;95. doi: 10.1016/j.jns.2018.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.12.035</ArticleId><ArticleId IdType="pubmed">30597420</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong I., Deelchand D.K., Eberly L.E., Marja&#x144;ska M., Manousakis G., Guliani G., Walk D., &#xd6;z G. Neurochemical correlates of functional decline in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:294&#x2013;301. doi: 10.1136/jnnp-2018-318795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318795</ArticleId><ArticleId IdType="pmc">PMC6467050</ArticleId><ArticleId IdType="pubmed">30467209</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry J.D., Cudkowicz M.E., Windebank A.J., Staff N.P., Owegi M., Nicholson K., McKenna-Yasek D., Levy Y.S., Abramov N., Kaspi H., et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. 2019;93:e2294&#x2013;e2305. doi: 10.1212/WNL.0000000000008620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008620</ArticleId><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J., Heiman-Patterson T., Pioro E.P., Wiedau-Pazos M., Liu S., Zhang J., Agnese W., Apple S. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of study 19 (MCI186-19) Muscle Nerve. 2019 doi: 10.1002/mus.26740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26740</ArticleId><ArticleId IdType="pmc">PMC7004197</ArticleId><ArticleId IdType="pubmed">31621933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro D., Consonni D., Fini N., Fasano A., Del Giovane C., Mandrioliet J., Emilia Romagna Registry for ALS (ERRALS) Group Amyotrophic lateral sclerosis: A comparison of two staging systems in a population-based study. Eur. J. Neurol. 2016;23:1426&#x2013;1432. doi: 10.1111/ene.13053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13053</ArticleId><ArticleId IdType="pubmed">27238551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Wei Q.-Q., Chen Y., Cao B., Ou R., Hou Y., Yuan X., Zhang L., Liu H., Shang H. Clinical staging of amyotrophic lateral sclerosis in chinese patients. Front. Neurol. 2018;9 doi: 10.3389/fneur.2018.00442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00442</ArticleId><ArticleId IdType="pmc">PMC6018204</ArticleId><ArticleId IdType="pubmed">29971035</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C., Newton J., Lonergan K., Chiwera T., Booth T., Chandran S., Colville S., Heverin M., Mays I., Pal S., et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91:e1370&#x2013;e1380. doi: 10.1212/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Moglia C., Canosa A., Manera U., Vasta R., Brunetti M., Barberis M., Corrado L., D&#x2019;Alfonso S., Bersano E., et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019;93:e984&#x2013;e994. doi: 10.1212/WNL.0000000000008063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008063</ArticleId><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W., Kiernan M.C. A unique account of ALS in China: Exploring ethnic heterogeneity. J. Neurol. Neurosurg. Psychiatry. 2015;86:1051&#x2013;1052. doi: 10.1136/jnnp-2015-311293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311293</ArticleId><ArticleId IdType="pubmed">26134851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q., Chen X., Zheng Z., Huang R., Guo X., Cao B., Zhao B., Shang H. Clinical features of amyotrophic lateral sclerosis in south-west China. Amyotroph. Lateral Scler. Front. Degener. 2015;16:512&#x2013;519. doi: 10.3109/21678421.2015.1069849.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1069849</ArticleId><ArticleId IdType="pubmed">26203659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui F., Liu M., Chen Y., Huang X., Cui L., Fan D., Pu C., Lu J., Zhou D., Zhang C., et al. Epidemiological characteristics of motor neuron disease in Chinese patients. Acta Neurol. Scand. 2014;130:111&#x2013;117. doi: 10.1111/ane.12240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12240</ArticleId><ArticleId IdType="pubmed">24689740</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H., Atsuta N., Nakamura R., Hirakawa A., Watanabe H., Ito M., Senda J., Katsuno M., Izumi Y., Morita M., et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Front. Degener. 2014;16:230&#x2013;236. doi: 10.3109/21678421.2014.990036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.990036</ArticleId><ArticleId IdType="pubmed">25548957</ArticleId></ArticleIdList></Reference><Reference><Citation>Manera U., Calvo A., Daviddi M., Canosa A., Vasta R., Torrieri M.C., Grassano M., Brunetti M., D&#x2019;Alfonso S., Corrado L., et al. Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: A population-based study. J. Neurol. Neurosurg. Psychiatry. 2020;91:291&#x2013;297. doi: 10.1136/jnnp-2019-321153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321153</ArticleId><ArticleId IdType="pubmed">31871138</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A., Martinelli I., Bello L., Querin G., Puthenparampil M., Ruggero S., Toffanin E., Cagnin A., Briani C., Pegoraro E., et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525&#x2013;532. doi: 10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi D., Atsuta N., Watanabe H., Nakamura R., Hirakawa A., Ito M., Watanabe H., Katsuno M., Izumi Y., Morita M., et al. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. J. Neurol. 2016;263:1129&#x2013;1136. doi: 10.1007/s00415-016-8109-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8109-0</ArticleId><ArticleId IdType="pubmed">27083563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhenfei L., Shiru D., Xiaomeng Z., Cuifang C., Yaling L. Discontiguous or contiguous spread patterns affect the functional staging in patients with sporadic amyotrophic lateral sclerosis. Front. Neurol. 2019:10. doi: 10.3389/fneur.2019.00523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00523</ArticleId><ArticleId IdType="pmc">PMC6540586</ArticleId><ArticleId IdType="pubmed">31191429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Wei Q.-Q., Chen Y., Cao B., Ou R., Hou Y., Yuan X., Zhang L., Liu H., Shang H. Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:53&#x2013;60. doi: 10.1080/21678421.2018.1550516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550516</ArticleId><ArticleId IdType="pubmed">30784318</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers H., Grupstra H., Nollet F., van den Berg L.H., Beelen A. Prognostic factors for the course of functional status of patients with ALS: A systematic review. J. Neurol. 2015;262:1407&#x2013;1423. doi: 10.1007/s00415-014-7564-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7564-8</ArticleId><ArticleId IdType="pubmed">25385051</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Jozsa F., Al-Chalabi A. Nonmotor symptoms in amyotrophic lateral sclerosis: A systematic review. Int. Rev. Neurobiol. 2017;134:1409&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">28805578</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge R., Mills R., Tennant A., Diggle P.J., Young C.A., Tonic Study Group Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature. J. Neurol. 2020;267:607&#x2013;615. doi: 10.1007/s00415-019-09615-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09615-3</ArticleId><ArticleId IdType="pmc">PMC7035222</ArticleId><ArticleId IdType="pubmed">31696295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q., Chen X., Cao B., Ou R., Zhao B., Wu Y., Shang H. Associations between neuropsychiatric symptoms and cognition in Chinese patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2016;17:358&#x2013;365. doi: 10.3109/21678421.2016.1154574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1154574</ArticleId><ArticleId IdType="pubmed">26962892</ArticleId></ArticleIdList></Reference><Reference><Citation>Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: Current perspectives. Nat. Sci. Sleep. 2019;11:97&#x2013;111. doi: 10.2147/NSS.S183504.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NSS.S183504</ArticleId><ArticleId IdType="pmc">PMC6701267</ArticleId><ArticleId IdType="pubmed">31496852</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Huang Y., Tai H., Zhang K., Wang Z., Shen D., Fu H., Su N., Shi J., Ding Q., et al. Excessive daytime sleepiness in Chinese patients with sporadic amyotrophic lateral sclerosis and its association with cognitive and behavioural impairments. J. Neurol. Neurosurg. Psychiatry. 2018;89:1038&#x2013;1043. doi: 10.1136/jnnp-2018-318810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318810</ArticleId><ArticleId IdType="pubmed">30045943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>